Seattle Genetics, Inc. (NASDAQ:SGEN) is a biotechnology company involved in developing antibody-based therapies for the treatment of cancer.
Seattle Genetics, Inc. (NASDAQ:SGEN) announced several ADCETRIS (brentuximab vedotin) data presentations at the 13th International Conference on Malignant Lymphoma (ICML) being held June …
Seattle Genetics, Inc. (NASDAQ:SGEN) and Unum Therapeutics announced that the two companies have entered into a strategic collaboration and license agreement to develop …
Seattle Genetics, Inc. (NASDAQ:SGEN) announced several ADCETRIS (brentuximab vedotin) data presentations in the AETHERA post-transplant consolidation setting for Hodgkin lymphoma (HL) and in …
Seattle Genetics, Inc. (NASDAQ:SGEN) announced that data from multiple proprietary and collaborator antibody-drug conjugate (ADC) programs will be highlighted in more than 10 …
Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that the U.
Seattle Genetics, Inc. (NASDAQ:SGEN) today highlighted the company’s broad presence at the upcoming 106th Annual Meeting of the American Association for Cancer Research(AACR) …
(BUSINESS WIRE)–Jan. 21, 2015– Seattle Genetics, Inc.
Seattle Genetics (NASDAQ:SGEN) is a $4 billion biotechnology company focused on developing and commercializing innovative antibody-based therapies for the treatment of cancer. They …
H.C.
